• Publications
  • Influence
Guideline for the management of clinically localized prostate cancer: 2007 update.
Ian Thompson (Chair),* James Brantley Thrasher (Co-Chair),† Gunnar Aus,‡ Arthur L. Burnett,§ Edith D. Canby-Hagino, Michael S. Cookson,¶ Anthony V. D’Amico, Roger R. Dmochowski, David T. Eton,Expand
  • 1,096
  • 50
  • PDF
Patient engagement in research: a systematic review
BackgroundA compelling ethical rationale supports patient engagement in healthcare research. It is also assumed that patient engagement will lead to research findings that are more pertinent toExpand
  • 634
  • 42
  • PDF
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update
PURPOSE The American Urological Association Prostate Guideline Update Panel was charged with updating the Guidelines for Clinically Localized Prostate Cancer. In assessing outcomes with treatment, itExpand
  • 552
  • 41
Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales.
Magnitude differences in scores on a measure of quality of life that correspond to differences in function or clinical course are called clinically important differences (CIDs). Anchor-based andExpand
  • 612
  • 37
Rethinking the patient: using Burden of Treatment Theory to understand the changing dynamics of illness
BackgroundIn this article we outline Burden of Treatment Theory, a new model of the relationship between sick people, their social networks, and healthcare services. Health services face theExpand
  • 253
  • 21
  • PDF
What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592.
To assess the impact of disease and treatment on patients with advanced non-small cell lung cancer (NSCLC), we set out to determine a clinically meaningful change (CMC) on the Lung Cancer SubscaleExpand
  • 326
  • 19
Improving quality of life in men with prostate cancer: a randomized controlled trial of group education interventions.
Men who were recently treated for prostate cancer (N=250) were randomly assigned to a control group, a group education intervention (GE), or a group education-plus-discussion intervention (GED). BothExpand
  • 260
  • 17
  • PDF
Prostate cancer and health‐related quality of life: a review of the literature
With the established effectiveness of diverse treatments for prostate cancer, identification of the physical and psychosocial consequences of the disease and various treatments becomes critical. WeExpand
  • 284
  • 17
Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients.
OBJECTIVE We combined anchor- and distribution-based methods to establish minimally important differences (MIDs) for six Patient-Reported Outcomes Measurement Information System (PROMIS)-CancerExpand
  • 288
  • 13
Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer.
OBJECTIVE To determine clinically meaningful changes (CMCs) for the Functional Assessment of Cancer Therapy-Prostate (FACT-P). METHODS We obtained data from a Phase III trial of atrasentan inExpand
  • 130
  • 13